- Home
- RVPHW vs ESQ Comparison
RVPHW vs ESQ Comparison
Compare RVPHW & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- ESQ
- Stock Information
- Founded
- RVPHW 2018
- ESQ 2006
- Country
- RVPHW United States
- ESQ United States
- Employees
- RVPHW 14
- ESQ N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- ESQ Commercial Banks
- Sector
- RVPHW Health Care
- ESQ Finance
- Exchange
- RVPHW Nasdaq
- ESQ Nasdaq
- Market Cap
- RVPHW N/A
- ESQ N/A
- IPO Year
- RVPHW N/A
- ESQ 2017
- Fundamental
- Price
- RVPHW $0.05
- ESQ $87.93
- Analyst Decision
- RVPHW
- ESQ Hold
- Analyst Count
- RVPHW 0
- ESQ 3
- Target Price
- RVPHW N/A
- ESQ $92.50
- AVG Volume (30 Days)
- RVPHW 22.4K
- ESQ 72.3K
- Earning Date
- RVPHW 03-14-2025
- ESQ 07-24-2025
- Dividend Yield
- RVPHW N/A
- ESQ 0.77%
- EPS Growth
- RVPHW N/A
- ESQ 13.51
- EPS
- RVPHW N/A
- ESQ 5.27
- Revenue
- RVPHW N/A
- ESQ $124,132,000.00
- Revenue This Year
- RVPHW N/A
- ESQ N/A
- Revenue Next Year
- RVPHW N/A
- ESQ $10.72
- P/E Ratio
- RVPHW N/A
- ESQ $17.22
- Revenue Growth
- RVPHW N/A
- ESQ 14.72
- 52 Week Low
- RVPHW $0.13
- ESQ $44.55
- 52 Week High
- RVPHW $0.15
- ESQ $92.50
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- ESQ 59.12
- Support Level
- RVPHW N/A
- ESQ $88.48
- Resistance Level
- RVPHW N/A
- ESQ $91.71
- Average True Range (ATR)
- RVPHW 0.00
- ESQ 1.87
- MACD
- RVPHW 0.00
- ESQ -0.40
- Stochastic Oscillator
- RVPHW 0.00
- ESQ 60.56
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.